

PEDIATRIX MEDICAL GROUP INC

Form 8-K

March 22, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT**
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (date of earliest event reported): March 19, 2007
PEDIATRIX MEDICAL GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)

Florida

001-12111

65-0271219

**(State or Other Jurisdiction of
Incorporation)**

**(Commission File
Number)**

**(IRS Employer
Identification No.)**

**1301 Concord Terrace
Sunrise, Florida 33323**

(Address of principal executive office)

Registrant's telephone number, including area code (954) 384-0175

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed by Pediatrix Medical Group, Inc. (the Company) in its press release dated February 28, 2007 and its Form 8-K filed with the Securities and Exchange Commission on March 1, 2007, the Company was not able to file its 2006 Annual Report on Form 10-K (the 2006 Form 10-K) in a timely manner because of the ongoing review of the Company's stock option practices. On March 19, 2007, the Company received a letter from the New York Stock Exchange, Inc. (the NYSE) informing the Company that, as a result of its failure to timely file its Form 10-K, it is subject to the procedures specified in Section 802.01E (SEC Annual Report Timely Filing Criteria) of the NYSE's Listed Company Manual. Section 802.01E, among other things, provides that the NYSE will closely monitor the status of the Company's 2006 Form 10-K filing and related public disclosures for up to a six-month period from its due date. If the Company has not filed its 2006 Form 10-K within six months of the filing due date, the NYSE will, in its sole discretion, determine whether the Company should be given up to an additional six months to file its 2006 Form 10-K. The letter also notes that regardless of these procedures, the NYSE may commence delisting proceedings at any time during the period that is available to complete the filing if the circumstances warrant. The Company is working to complete the review and file the 2006 Form 10-K as soon as possible.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PEDIATRIX MEDICAL GROUP, INC.

Date: March 22, 2007

By: /s/ Karl B. Wagner
Name: Karl B. Wagner
Title: Chief Financial Officer